George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-World shares rise on recovery hopes after record November

Tue, 01st Dec 2020 13:47

(Adds details, updates prices, changes dateline)

* World shares up 0.4%, U.S. futures up sharply

* Vaccine hopes drives optimism after EZ factory recovery
falters

* China factory activity growth hits decade high in November

* U.S. dollar weakens, Bitcoin off record highs

* Oil volatile after OPEC+ talks delay, copper up

By Danilo Masoni

MILAN, Dec 1 (Reuters) - World shares rose to just below
record peaks on Tuesday after factory surveys boosted
expectations of a recovery from the COVID-19 downturn, with
drugmakers seeking fast approval for vaccines and authorities
looking set to maintain stimulus.

Bets on more easing from the U.S. Federal Reserve to help
the pandemic-hit economy through the winter weighed on the
dollar as riskier currencies rose, while crude prices struggled
to join the bounce after oil-producing countries delayed a
decision on output cuts.

The MSCI world equity index, which tracks
shares in 49 countries, was up 0.4% by 1323 GMT.

Breakthroughs in vaccine developments from top drugmakers
Pfizer, Moderna and AstraZeneca in
November along with a market-friendly outcome of the U.S.
presidential election helped the index score its best month on
record, up 12% to new all-time peaks.

"We believe the rally can continue, with the current
pipeline of expected vaccine rollouts in line with our central
scenario of widespread availability in the second quarter of
2021," said Mark Haefele, Chief Investment Officer at UBS Global
Wealth Management in Zurich.

"We also believe that a divided U.S. government - which
looks the most likely outcome - is no impediment to a rising
market," he added.

In Europe the pan-regional STOXX 600 benchmark was
up 0.7%, while U.S. stock index futures also pointed to a strong
start on Wall Street, with investors focusing on November
manufacturing surveys from Europe and the United States.

Euro zone factory surveys were less upbeat than China's as
growth in the region cooled last month from a 32-month high on
renewed lockdown measures. However, optimism did improve amid
progress in developing COVID-19 vaccines.

In the UK, factories recorded their fastest growth in almost
three years last month.

Earlier the MSCI's broadest index of Asia-Pacific shares
outside Japan closed up 1.3%. China's blue-chip
CSI300 index rose 2.2% after a business survey showed
activity in China's factory sector accelerated at the fastest
pace in a decade in November.

Japan's Nikkei closed near a 29-1/2-year high.

"What we are seeing today is that upward trend reasserting
itself, given the positive news on the vaccine front, China's
growth picking up, and the tremendous faith in the ability of
central banks to keep the markets afloat," said Stephen Miller,
market strategist for GSFM Funds Management.

Pfizer on Tuesday said it had asked for EU emergency
authorization of its vaccine, taking it closer to launch
following a similar move in the United States last month.

Moderna applied for U.S. authorization on Monday
after full results from a late-stage study showed it was 94.1%
effective with no serious safety concerns.

In foreign exchange markets, the dollar was under pressure
after closing out on Monday its worst month since July with a
little bounce, and as investors reckon on even more U.S.
monetary easing.

The dollar index was last down 0.2% to 91.758.

In a speech released late on Monday, Fed chair Jerome Powell
said a slowing recovery and a surging pandemic meant the U.S.
was entering a "challenging" few months, with the potential
deployment of a vaccine still facing hurdles.

The Fed holds its next policy meeting later this month.

That lifted the euro close to a three-month high,
up 0.4% at $1.1974, while risk-related currencies such as the
Canadian and Aussie dollar rose against the greenback.

Elsewhere sterling was up 0.5% after hitting a
three-month high as traders clung to hopes for a Brexit trade
deal before the year's end, despite the lack of tangible
progress.

Bitcoin was volatile, last down 6% after hitting
a record high earlier in the day.

Bond markets were quieter. Germany's 10-year bond yield
nudged off three-week lows at -0.564%, while
southern European debt yields also edged up, though they held
close to record lows ahead of next week's European Central Bank
meeting.

Data on Tuesday showing a bigger than expected drop in euro
zone inflation in November didn't move bond markets much but
cemented expectations for the ECB to take action.

"The message is clear for the ECB. As this has been the base
case for some time now, it will without a doubt make the ECB
loosen policy once again," said ING senior economist Bert Colijn
in Amsterdam.

U.S. 10-year yields were up slightly at 0.8602%
as the U.S. Congress began a two-week sprint to secure funding
and avoid a possible shutdown amid the coronavirus pandemic.

Metal markets were buoyant, reflecting the risk-on mood.
London copper prices pushed back towards Monday's 7-1/2-year
high, helped by the robust data from China.

Oil prices were volatile after leading producers delayed
talks on 2021 output policy, while the coronavirus pandemic
continued to sap fuel demand.

OPEC+ delayed talks on output policy for next year until
Thursday, sources told Reuters, as key players still disagreed
on how much oil they should pump amid weak demand.

Brent crude futures were last 0.2% lower at $47.8 a
barrel, while U.S. crude also eased 0.4% to $45.16.

(Reporting by Danilo Masoni in Milan, additional reporting by
Paulina Duran in Sydney; Editing by Mike Collett-White and Jan
Harvey)

More News
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.